Ho Jung An

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Jang Ho Cho, Sung Hee Lim, Ho Jung An et al. · Journal of Clinical Oncology · 2019 · 346 citations · Full text

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi‐Long Wu, Ying Cheng, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2020 · 249 citations

Oncology, Met Amplification, Medicine +10

Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma

Ho Jung An, Jeong Won Jang, Si Hyun Bae et al. · Liver Transplantation · 2012 · 75 citations · Full text

Soluble HSPB1 regulates VEGF-mediated angiogenesis through their direct interaction

Yoon-Jin Lee, Hae-Jun Lee, Seo-Hyun Choi et al. · Angiogenesis · 2012 · 72 citations

Angiogenesis, Vascular Biology, Soluble Hspb1 +6